Competitive intelligence
Who else is working on your target, and on what evidence
Atlas identifies the companies, universities, hospitals and research institutes active on your project's subject, from the trials, patents, grants and papers it already holds. Each organization gets a sourced profile; you decide who is a competitor, a partner or someone to watch.
What is competitive intelligence in biotech R&D?
Competitive intelligence in drug development maps the organizations working on the same target or indication: their molecules, trials, patents, funding and publications. Teams use it to position a program, anticipate readouts and spot potential partners. Built by hand, it means searching registries, patent offices and literature one organization at a time.
With Atlas
- Identifies organizations from the evidence already in your project
- Gives each one a factual reason for being listed, with its source
- Assembles a profile: programs, trials, patents, grants, papers, timeline
- Summarizes it briefly, from that evidence only, with a date
Step 1 of 3
Organizations come from your evidence, each with a reason
An organization is listed because the project’s evidence names it in a role: sponsor of a trial on the target, applicant on a relevant patent family, holder of a grant, documented affiliation of a paper. A name that only appears in a reference list is not enough.
In the KRAS G12C example, the phase 3 trials alone bring in Eli Lilly and Company, Amgen, Mirati Therapeutics Inc., Hoffmann-La Roche.
One evidence type only, trial sponsorship, from the 50 trials of the example project, read on 30 Oct 2026. Atlas adds patents, grants and papers.
Step 2 of 3
One profile per organization, built from sources
The profile brings together what is scattered across modules: the organization’s programs, trials, patents, grants and publications, on a timeline, with a development pipeline and an activity chart when the data allows.
Different roles stay distinct, and names are merged with care: a subsidiary, a parent company or a namesake is not folded into another organization on resemblance alone.
- Programs
- The molecules and indications the evidence attributes to the organization
- Trials
- Trials it sponsors or collaborates on, with phase and status
- Patents
- Patent families where it is an applicant
- Grants
- Public grants it holds, from NIH RePORTER and CORDIS
- Publications
- Papers with a documented affiliation, funding or conflict-of-interest link
- Timeline
- Dated events across all of the above
Step 3 of 3
A short summary you can check, line by line
Atlas does not crawl company websites or pull in unsourced web content: everything in a profile comes from registries, patent offices, grant databases and the literature, and opens on the record it came from.
No threat score, no ranking of rivals: the judgment stays with you.
- Generated from the evidence in the profile, nothing else
- Each statement opens on its source in the inspector
- Dated, and refreshed when you ask for it
Map the organizations around your target
We set up a project on your disease and target with you and walk through the organizations Atlas identifies.
Request a demoExample: lead sponsors as registered on ClinicalTrials.gov for the 50 trials of the Atlas project “KRAS G12C NSCLC Landscape”, read on 30 Oct 2026. Sponsor names are not normalized: an acquired company keeps the name under which it registered the trial.
